{"id":962163,"date":"2026-05-13T08:34:00","date_gmt":"2026-05-13T12:34:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/"},"modified":"2026-05-13T08:34:00","modified_gmt":"2026-05-13T12:34:00","slug":"bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/","title":{"rendered":"Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BOSTON, May  13, 2026  (GLOBE NEWSWIRE) &#8212; Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective May 8, 2026, it awarded an inducement grant to Christopher Sarchi under Bicara\u2019s 2026 Inducement Plan as a material inducement to his commencement of employment as Bicara\u2019s Chief Commercial Officer.<\/p>\n<p align=\"justify\">Mr. Sarchi received a non-qualified stock option to purchase 282,240 shares of Bicara\u2019s common stock, par value $0.0001 per share, with an exercise price of $22.58 per share, equal to the closing price of Bicara\u2019s common stock as reported by Nasdaq on May 8, 2026. One-fourth of the shares vest on the first anniversary of Mr. Sarchi\u2019s start date, with the remaining shares vesting in 12 equal quarterly installments thereafter, subject to his continued service with Bicara through each applicable vesting date.<\/p>\n<p align=\"justify\">Mr. Sarchi\u2019s award was granted outside of Bicara\u2019s stockholder-approved equity incentive plans and is pursuant to Bicara\u2019s 2026 Inducement Plan, which was adopted by Bicara\u2019s board of directors in January 2026. The award was approved by the compensation committee of Bicara\u2019s board of directors, which is comprised solely of independent directors, as a material inducement to the employee entering into employment with Bicara in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p align=\"justify\">\n        <strong>About Bicara Therapeutics<br \/><\/strong>Bicara\u00a0is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors.\u00a0Bicara has built a platform designed to\u00a0facilitate\u00a0the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site. This approach was deployed in the development of\u00a0Bicara\u2019s\u00a0lead program ficerafusp alfa, formerly BCA101, a bifunctional epidermal growth factor receptor (EGFR) directed monoclonal antibody bound to a human transforming growth factor beta (TGF-\u03b2) ligand trap. By combining these two clinically validated targets, ficerafusp alfa has the potential to exert potent anti-tumor activity by simultaneously blocking both cancer cell-intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF-\u03b2\u00a0signaling\u00a0within the tumor microenvironment (TME). Ficerafusp alfa directs the TGF-\u03b2\u00a0inhibitor\u00a0into the immediate TME through the binding of EGFR on tumor cells, which Bicara believes will lead to deep and durable responses and an increase in overall survival, while reducing the potential<strong>\u00a0<\/strong>adverse effects previously<strong>\u00a0<\/strong>associated with systemic TGF-\u03b2 inhibition. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6krkrSn-lRafgY13Z9L8hak5btUDgXZdj0s_3eoVpbXGshKdRE0js4M_c9ZWUsSpzMBVjmk9jWRuZ4JlQ9vqXtn-cqmyRbiiz8s55n3VDRYCkBtsVUwg6UL8VhtC1AkQX9on0Lk4bmsw0c5HKyCio8eOQOpGd4-eHCoMD3QXcWJ_Hjw3p0j9yJvJxW-nTj1mLpMvDD_3SWlv-3hjRJLbExnHUSevLse31VNZtmYKfOA=\" rel=\"nofollow\" target=\"_blank\">www.bicara.com<\/a>\u00a0or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=o_fAN5D_A84UtDAkPLcR8Q0hfOHfbkFpAJOGcRcbd8eGvEILuA9VDYsKTk-LpXAw4H9N0iMUmPB-lKpB6JGd0Uo83o89f1pLdD05a26MYKAGM692AMeFwY8aaitPQRTe\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=G-f7RtT8n6bzWMyHf6GaG-IzG3xbB9Lnc7wnxugI0kkChbj-70ljzGTrPZWOM5JsrPVWAndRUKnCEOYvKbL45A==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Rachel Frank<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-eh8C4QsEmD8nFwT1jZyfMkXPAlGTD9k_a2gguDvjCssSLAdq2vVHs732X1rYXWv4sJliEaAlr3vXtaRFrlGBg==\" rel=\"nofollow\" target=\"_blank\">IR@bicara.com<\/a><\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Tim Palmer<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iTPeZKHewgXx5N3ikqtyEIhkUA7-RPpLucUvdeU6ZAsFxL3-BIjWKOYm7jkxOwH0291b1G8XlhjzThALuRjmcO-aLUWHb_75x_cphOQq4To=\" rel=\"nofollow\" target=\"_blank\">tim.palmer@bicara.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODcxOSM3NTk4ODk2IzIyNTA4NzQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTU4NGU4MzgtZTg5MC00NWFkLWEwNmYtMDcwYTc2MTMzYzdiLTEyNjI0MjctMjAyNi0wNS0xMy1lbg==\/tiny\/Bicara-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, May 13, 2026 (GLOBE NEWSWIRE) &#8212; Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective May 8, 2026, it awarded an inducement grant to Christopher Sarchi under Bicara\u2019s 2026 Inducement Plan as a material inducement to his commencement of employment as Bicara\u2019s Chief Commercial Officer. Mr. Sarchi received a non-qualified stock option to purchase 282,240 shares of Bicara\u2019s common stock, par value $0.0001 per share, with an exercise price of $22.58 per share, equal to the closing price of Bicara\u2019s common stock as reported by Nasdaq on May 8, 2026. One-fourth of the shares vest on the first anniversary of Mr. Sarchi\u2019s start date, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-962163","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, May 13, 2026 (GLOBE NEWSWIRE) &#8212; Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective May 8, 2026, it awarded an inducement grant to Christopher Sarchi under Bicara\u2019s 2026 Inducement Plan as a material inducement to his commencement of employment as Bicara\u2019s Chief Commercial Officer. Mr. Sarchi received a non-qualified stock option to purchase 282,240 shares of Bicara\u2019s common stock, par value $0.0001 per share, with an exercise price of $22.58 per share, equal to the closing price of Bicara\u2019s common stock as reported by Nasdaq on May 8, 2026. One-fourth of the shares vest on the first anniversary of Mr. Sarchi\u2019s start date, &hellip; Continue reading &quot;Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T12:34:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODcxOSM3NTk4ODk2IzIyNTA4NzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-05-13T12:34:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/\"},\"wordCount\":444,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODcxOSM3NTk4ODk2IzIyNTA4NzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/\",\"name\":\"Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODcxOSM3NTk4ODk2IzIyNTA4NzQ=\",\"datePublished\":\"2026-05-13T12:34:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODcxOSM3NTk4ODk2IzIyNTA4NzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxODcxOSM3NTk4ODk2IzIyNTA4NzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/","og_locale":"en_US","og_type":"article","og_title":"Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"BOSTON, May 13, 2026 (GLOBE NEWSWIRE) &#8212; Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective May 8, 2026, it awarded an inducement grant to Christopher Sarchi under Bicara\u2019s 2026 Inducement Plan as a material inducement to his commencement of employment as Bicara\u2019s Chief Commercial Officer. Mr. Sarchi received a non-qualified stock option to purchase 282,240 shares of Bicara\u2019s common stock, par value $0.0001 per share, with an exercise price of $22.58 per share, equal to the closing price of Bicara\u2019s common stock as reported by Nasdaq on May 8, 2026. One-fourth of the shares vest on the first anniversary of Mr. Sarchi\u2019s start date, &hellip; Continue reading \"Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-13T12:34:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODcxOSM3NTk4ODk2IzIyNTA4NzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-05-13T12:34:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/"},"wordCount":444,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODcxOSM3NTk4ODk2IzIyNTA4NzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/","name":"Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODcxOSM3NTk4ODk2IzIyNTA4NzQ=","datePublished":"2026-05-13T12:34:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODcxOSM3NTk4ODk2IzIyNTA4NzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxODcxOSM3NTk4ODk2IzIyNTA4NzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bicara-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=962163"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962163\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=962163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=962163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=962163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}